A low arm and leg muscle mass to total body weight ratio is associated with an increased prevalence of metabolic syndrome: The Korea National Health and Nutrition Examination Survey 2010-2011

2016 ◽  
Vol 24 (5) ◽  
pp. 655-663 ◽  
Author(s):  
Yong Hwan Kim ◽  
Wi-Young So
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
Muscle Mass ◽  
Weight Ratio ◽  
Total Body Weight ◽  
Nutrition Examination Survey ◽  
Body Weight Ratio ◽  
Health And Nutrition ◽  
Leg Muscle ◽  
Total Body

scholarly journals Creatinine/(cystatin C × body weight) ratio is associated with skeletal muscle mass index

2020 ◽  
Vol 67 (7) ◽  
pp. 733-740 ◽  
Author(s):  
Kensuke Nishida ◽  
Yoshitaka Hashimoto ◽  
Ayumi Kaji ◽  
Takuro Okamura ◽  
Ryousuke Sakai ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Body Weight ◽  
Muscle Mass ◽  
Cystatin C ◽  
Skeletal Muscle Mass ◽  
Weight Ratio ◽  
Body Weight Ratio ◽  
Skeletal Muscle Mass Index

Low muscle mass is associated with metabolic syndrome only in nonobese young adults: the Korea National Health and Nutrition Examination Survey 2008-2010

2015 ◽  
Vol 35 (12) ◽  
pp. 1070-1078 ◽  
Author(s):  
Byung Chul Kim ◽  
Mee Kyoung Kim ◽  
Kyungdo Han ◽  
Sae-Young Lee ◽  
Seung-Hwan Lee ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Young Adults ◽  
Muscle Mass ◽  
National Health ◽  
Nutrition Examination Survey ◽  
Health And Nutrition

scholarly journals Mesenchymal Stem Cell-Derived Exosomes Protect Muscle Loss by miR-145-5p Activity Targeting Activin A Receptors

Cells ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 2169
Author(s):  
Kyung-Ah Cho ◽  
Da-Won Choi ◽  
Yu-Hee Kim ◽  
Jungwoo Kim ◽  
Kyung-Ha Ryu ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Body Weight ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Total Body Weight ◽  
Activin A ◽  
Dependent Manner ◽  
Muscle Loss ◽  
Total Body

Skeletal muscle mass is decreased under a wide range of pathologic conditions. In particular, chemotherapy is well known for inducing muscle loss and atrophy. Previous studies using tonsil-derived mesenchymal stem cells (T-MSCs) or a T-MSC-conditioned medium showed effective recovery of total body weight in the chemotherapy-preconditioned bone marrow transplantation mouse model. This study investigated whether extracellular vesicles of T-MSCs, such as exosomes, are a key player in the recovery of body weight and skeletal muscle mass in chemotherapy-treated mice. T-MSC exosomes transplantation significantly decreased loss of total body weight and muscle mass in the busulfan-cyclophosphamide conditioning regimen in BALB/c recipient mice containing elevated serum activin A. Additionally, T-MSC exosomes rescued impaired C2C12 cell differentiation in the presence of activin A in vitro. We found that T-MSC exosomes possess abundant miR-145-5p, which targets activin A receptors, ACVR2A, and ACVR1B. Indeed, T-MSC exosomes rescue muscle atrophy both in vivo and in vitro via miR-145-5p dependent manner. These results suggest that T-MSC exosomes have therapeutic potential to maintain or improve skeletal muscle mass in various activin A elevated pathologic conditions.

Proposed corrections in the KERR method on estimating total body weight and calculating muscle mass in athletes

1992 ◽  
Vol 25 (7) ◽  
pp. 702
Author(s):  
F.J. Berral ◽  
A. Escribano ◽  
C.J. Berral ◽  
J.L.Lancho Alonso ◽  
E. DeRose
Keyword(s):  
Body Weight ◽  
Muscle Mass ◽  
Total Body Weight ◽  
Total Body

scholarly journals PDE9 Inhibition By IMR-687 Improves Markers of Beta-Thalassemia in the Hbb th1/th1 Experimental Mouse Model

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 945-945
Author(s):  
Thiago Trovati Maciel ◽  
Caroline Carvalho ◽  
Rachel Rignault ◽  
Slimane Allali ◽  
Biree Andemariam ◽  
...  
Keyword(s):  
Body Weight ◽  
Mouse Model ◽  
Research Funding ◽  
Weight Ratio ◽  
Total Body Weight ◽  
Beta Thalassemia ◽  
Flow Cytometry Analysis ◽  
Publicly Traded ◽  
Once Daily ◽  
Total Body

Abstract Introduction Hbb th1/th1 mice lack functional beta-globin, leading to decreased hemoglobin (Hb) production, decreased mature red blood cells (RBCs), and ineffective erythropoiesis. The model mimics several of the pathological changes seen in beta-thalassemia. IMR-687 (tovinontrine) is a highly selective phosphodiesterase-9 (PDE9) inhibitor which increases intracellular cGMP. The aim of this study was to assess the effect of IMR-687 on markers of beta-thalassemia in the Hbb th1/th1 mouse model. Methods Eighteen Hbb th1/th1 mice were divided into three groups of six animals each and dosed once daily, by gavage, for 30 days with IMR-687 at 30 or 60 mg/kg/day or vehicle control. On day 30, blood was collected for routine hematology including measurement of Hb, reticulocytes and RBCs, and spleen tissue was dissociated to assess erythrocyte differentiation using flow cytometry analysis of immature (Ery.B: Ter119 highCD71 highFSC low) and mature (Ery.C: Ter119 highCD71 lowFSC low) erythroblast populations. Animals were observed daily for mortality and measured for total body weight (Day 0 and Day 30) and spleen to body weight ratio at necropsy (Day 30). Results After 30 days of treatment, the groups of mice treated with IMR-687 at 30 or 60 mg/kg/day showed a mean increase in Hb of 1.0 g/dL (p<0.05) and 1.5 g/dL (p<0.01), respectively, relative to vehicle controls. RBCs showed a statistically significant increase (p<0.05) following treatment with IMR-687 at 30 or 60 mg/kg/day (6.9 and 7.2 x10 6 cells/ml, respectively) relative to vehicle (6.2 x10 6 cells/ml). The number of reticulocytes decreased after treatment with IMR-687 (only in the 30 mg/kg/day group, 1.8 x10 6 cells/ml, p<0.05) relative to vehicle (2.2 x10 6 cells/ml). Flow cytometry analysis of spleens showed that both doses of IMR-687 increased (p<0.05) the percentage of Ery.C cells (24.2% and 28.5% in 30 and 60 mg/kg/day, respectively) relative to vehicle (16.6%,) and decreased (p<0.05) the percentage of Ery.B cells (38.4% and 36.9% in 30 and 60 mg/kg/day, respectively) relative to vehicle (43.5%), resulting in a maturation ratio (Ery.B/Ery.C) that favored mature RBCs. There were no deaths nor any significant differences in total body weight or spleen to body weight ratio in animals treated with IMR-687 relative to vehicle controls. Conclusions Administration of IMR-687 at 30 or 60 mg/kg/day for 30 days improved markers of disease progression in a mouse model of beta-thalassemia, as shown by a statistically significant increase in Hb and RBCs and decrease in reticulocytes as well as improved differentiation of splenic erythroblasts. Both dose levels of IMR-687 were well tolerated with no treatment-related deaths or abnormal clinical signs. These results support a role for IMR-687 in beta-thalassemia by enabling RBC maturation and improving ineffective erythropoiesis, key components in ameliorating disease pathology. Clinical testing of IMR-687 (up to 400 mg) as a once daily, oral tablet is currently ongoing in a Phase 2 study of patients with beta-thalassemia (NCT04411082). Figure 1 Figure 1. Disclosures Maciel: Imara Inc.: Research Funding. Carvalho: Imara Inc.: Research Funding. Rignault: Imara Inc.: Research Funding. Allali: Imara Inc.: Research Funding. OCain: Imara Inc.: Current Employment, Current equity holder in publicly-traded company. Ballal: Imara Inc.: Current Employment, Current equity holder in publicly-traded company.

scholarly journals Changes in skinfolds during pregnancy

1967 ◽  
Vol 21 (2) ◽  
pp. 439-451 ◽  
Author(s):  
Nan R. Taggart ◽  
Ruth M. Holliday ◽  
W. Z. Billewicz ◽  
F. E. Hytten ◽  
A. M. Thomson
Keyword(s):  
Body Weight ◽  
Post Partum ◽  
Weight Ratio ◽  
Dry Weight ◽  
Total Body Weight ◽  
Skinfold Thickness ◽  
Maternal Weight ◽  
Consistent Manner ◽  
Total Body ◽  
Highly Correlated

1. Skinfold thicknesses at seven sites were measured during and after pregnancy in eighty- four women; in forty-eight of these, total body water was measured concurrently.2. Early in pregnancy (10 weeks) the skinfold measurements were highly correlated with each other and with maternal weight, ratio of observed weight to standard weight-for-height,‘dry’ (water-free) weight, and with calculated estimates of body fat.3. At nearly all sites, skinfold thicknesses increased up to about 30 weeks of pregnancy. Increases were greater at ‘central’ and least at ‘peripheral’ sites, and were not proportional to the initial skinfold thickness.4. From 30 to 38 weeks of pregnancy, the patterns were variable: the mid-thigh skinfold continued to increase and at the other sites there was little change or a decrease.5. All sites decreased by a surprisingly large amount between 38 weeks of pregnancy and the end of the first post-partum week. The evidence suggests that this change, which was not related to the presence or absence of oedema, occurred about the time of parturition.6. From the end of the first post-partum week to 6–8 weeks post partum, the changes were again variable.7. The increase of skinfolds during pregnancy was greater in underweight than in overweight women, and in primiparae than in multiparae. The pattern of change was not affected in any consistent manner by oedema.8. The changes in skinfold thicknesses during pregnancy, especially up to about 30 weeks, showed patterns similar to those of total body-weight and ‘dry’ body-weight. A formula is given by means of which ‘dry’ weight can be predicted from five skinfolds, height and duration of gestation.

Sign in / Sign up

Export Citation Format

Share Document